These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12783616)

  • 1. Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease.
    Chu NR
    Expert Opin Biol Ther; 2003 Jun; 3(3):477-86. PubMed ID: 12783616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural HPV immunity and vaccination strategies.
    Stern PL; Brown M; Stacey SN; Kitchener HC; Hampson I; Abdel-Hady ES; Moore JV
    J Clin Virol; 2000 Oct; 19(1-2):57-66. PubMed ID: 11091148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine.
    Jochmus I; Schäfer K; Faath S; Müller M; Gissmann L
    Arch Med Res; 1999; 30(4):269-74. PubMed ID: 10573627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of human papillomavirus vaccines: from basic science to clinical trials.
    Berry JM; Palefsky JM
    Front Biosci; 2003 May; 8():s333-45. PubMed ID: 12700045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunologic aspects of infections with papillomaviruses. Prospects for a vaccine].
    Höpfl R; Heim K
    Hautarzt; 1996 Oct; 47(10):739-43. PubMed ID: 9036120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Perspectives for the development of vaccines and immunotherapy against cervico-uterine cancer].
    Guzmán-Rojas L; Alcocer-González JM; Madrid-Marina V
    Salud Publica Mex; 1998; 40(1):38-46. PubMed ID: 9567657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of vaccines in the prevention and treatment of cervical cancer.
    Davidson EJ; Kitchener HC; Stern PL
    Clin Oncol (R Coll Radiol); 2002 Jun; 14(3):193-200. PubMed ID: 12109821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment.
    Cornelison TL
    Curr Opin Oncol; 2000 Sep; 12(5):466-73. PubMed ID: 10975555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vaccination against human papillomavirus and against the cellular proliferation that it induces: facts and expectations].
    Giannouli C; Burny A; Hallez S
    J Gynecol Obstet Biol Reprod (Paris); 2000 May; 29(3):258-60. PubMed ID: 10804365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papillomavirus-like particles for serology and vaccine development.
    Kirnbauer R
    Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus vaccines in development: if they're successful in clinical trials, how will they be implemented?
    Shaw AR
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S246-8. PubMed ID: 16213009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging human papillomavirus vaccines.
    Christensen ND
    Expert Opin Emerg Drugs; 2005 Feb; 10(1):5-19. PubMed ID: 15757400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
    Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
    J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for a vaccine against human papillomavirus.
    Hines JF; Ghim S; Schlegel R; Jenson AB
    Obstet Gynecol; 1995 Nov; 86(5):860-6. PubMed ID: 7566866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of mature dendritic cells for anti-human papillomavirus peptide-based vaccination in transplant patients.
    Mariat C; Alamartine E; Sabido O; Berthoux F
    Transplant Proc; 2002 Nov; 34(7):2836-7. PubMed ID: 12431627
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunobiology of papillomavirus infections.
    Stanley MA
    J Reprod Immunol; 2001; 52(1-2):45-59. PubMed ID: 11600177
    [No Abstract]   [Full Text] [Related]  

  • 18. Animal models for development of therapeutic HPV16 vaccines (review).
    Bubeník J
    Int J Oncol; 2002 Jan; 20(1):207-12. PubMed ID: 11743666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for the prevention of cervical cancer by human papillomavirus vaccination.
    Williamson AL; Passmore JA; Rybicki EP
    Best Pract Res Clin Obstet Gynaecol; 2005 Aug; 19(4):531-44. PubMed ID: 16150392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccinating women against premature death: summary of an International Workshop, Helsinki, Finland, 10.01.2000.
    Lehtinen M; Dillner J; Paavonen J
    Vaccine; 2001 Jan; 19(11-12):1347-52. PubMed ID: 11252250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.